# Blood Mechanical Intelligence: From Force Sensing to Precision Mechanomedicine

## TL;DR

Blood cells use mechanical cues to adapt and function, a concept called mechanical intelligence, which has implications for both health and disease.

## Contribution

The paper introduces the concept of mechanical intelligence in blood cells and outlines its role in mechanomedicine.

## Key findings

- Mechanosensitive receptors and cytoskeletal feedback link mechanical cues to cellular functions in blood cells.
- Repeated mechanical exposure leads to mechanical memory, which can enhance physiological performance or contribute to disease.
- Mechanodiagnostics and mechanotherapy are proposed as tools for diagnosing and treating mechanical dysfunctions in blood.

## Abstract

Blood is a force-rich system. Beyond biochemistry, blood cells continually sense shear, stretch, and substrate rigidity, encode these inputs into biochemical and structural state changes, and adjust future behavior. We term this mechanical intelligence: an operational framework encompassing mechanosense, learning and memory, decision-making, and adaptive evolution. We synthesize evidence across red blood cells (RBCs), leukocytes, and platelets showing how mechanosensitive receptors (Piezo-type mechanosensitive ion channel component 1, glycoprotein Ib-IX-V complex, and integrins), cytoskeletal feedback, and nuclear effectors (Yes-associated protein/transcriptional coactivator with PDZ-binding motif and nuclear factor κB) couple mechanical cues to cellular states and functions (oxygen delivery, immune surveillance, and hemostasis). Repeated mechanical exposures produce mechanical memory (e.g., RBC fatigue and shape memory, shear-primed platelet hyperreactivity, and stiffness-modulated leukocyte transmigration) that improves performance in physiological contexts but contributes to pathology when dysregulated (vaso-occlusion, thrombosis, and inflammaging). We outline mechanodiagnostics (single-cell deformability cytometry, atomic force microscopy, and microfluidic thrombus profiling) and mechanotherapy (ion channel modulators, engineering cells, and mechanocompatible devices) and propose reporting standards, readiness levels, and validation pathways.